Publicaciones en colaboración con investigadores/as de University of Calgary (41)

2024

  1. Anticoagulation Use and Endovascular Thrombectomy in Patients with Large Core Stroke: A Secondary Analysis of the SELECT2 Trial

    Annals of Neurology, Vol. 96, Núm. 5, pp. 887-894

  2. Clinical relevance of intracranial hemorrhage after thrombectomy versus medical management for large core infarct: a secondary analysis of the SELECT2 randomized trial

    Journal of NeuroInterventional Surgery, pp. 1-8

  3. Endovascular Thrombectomy Treatment Effect in Direct vs Transferred Patients with Large Ischemic Strokes: A Prespecified Analysis of the SELECT2 Trial

    JAMA Neurology, Vol. 81, Núm. 4, pp. 327-335

  4. Endovascular Thrombectomy for Large Ischemic Stroke Across Ischemic Injury and Penumbra Profiles

    JAMA, Vol. 331, Núm. 9, pp. 750-763

  5. Endovascular thrombectomy plus medical care versus medical care alone for large ischaemic stroke: 1-year outcomes of the SELECT2 trial

    The Lancet, Vol. 403, Núm. 10428, pp. 731-740

  6. Mortality, perioperative complications and surgical timelines in hip fracture patients: Comparison of the Spanish with the non-Spanish Cohort of the HIP ATTACK-1 trial

    Injury, Vol. 55, Núm. 11

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Clinical outcome of patients with mild pre-stroke morbidity following endovascular treatment: a HERMES substudy

    Journal of NeuroInterventional Surgery, Vol. 15, Núm. 3, pp. 214-220

  3. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031

  4. Profiling the immune landscape in mucinous ovarian carcinoma

    Gynecologic Oncology, Vol. 168, pp. 23-31

  5. Trial of Endovascular Thrombectomy for Large Ischemic Strokes.

    New England Journal of Medicine, Vol. 388, Núm. 14, pp. 1259-1271

  6. p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study

    Journal of Pathology: Clinical Research, Vol. 9, Núm. 3, pp. 208-222

2022

  1. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

    Blood, Vol. 139, Núm. 6, pp. 835-844

  2. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

    Blood, Vol. 139, Núm. 4, pp. 492-501

2021

  1. Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefit

    Schizophrenia Research, Vol. 227, pp. 10-17

  2. Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

    American Journal of Hematology, Vol. 96, Núm. 6, pp. 708-718

  3. Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

    Journal of Hematology and Oncology

  4. Global impact of COVID-19 on stroke care

    International Journal of Stroke, Vol. 16, Núm. 5, pp. 573-584

  5. Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results

    Journal of Cancer Research and Clinical Oncology, Vol. 147, Núm. 2, pp. 619-631

  6. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382